A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Golimumab
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 14 Aug 2017 Planned End Date changed from 17 Jun 2019 to 6 Sep 2019.
    • 22 Jul 2017 Trial has been completed in Poland. (end date: 2017-05-17).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top